Cargando…

Ceftazidime dosage regimen recommendations in burn patients based on a Monolix population pharmacokinetic study

Detalles Bibliográficos
Autores principales:	Ruiz, S, Conil, JM, Georges, B, Ravat, F, Seguin, T, Letocart, P, Fourcade, O, Saivin, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363484/ http://dx.doi.org/10.1186/cc10673

Ejemplares similares

Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil
por: Traynard, Pauline, et al.
Publicado: (2020)

Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study
por: Minville, Vincent, et al.
Publicado: (2011)

Dynamics of the dosage of citrate-calciuminfusion regimens as anticoagulation in continuous venovenous hemodiafiltration
por: Marin Mateos, H, et al.
Publicado: (2015)

Pharmacokinetics of micafungin in patients with severe burn injuries
por: Sasaki, J, et al.
Publicado: (2012)

Pharmacokinetics of micafungin in patients with severe burn injuries
por: Sasaki, J, et al.
Publicado: (2011)

Relation between ventilatory pressures and intra-abdominal pressure
por: Ashraf, A, et al.
Publicado: (2008)

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
por: Chan, Phylinda L. S., et al.
Publicado: (2010)

Ceftazidime administered by continuous perfusion can improve the prognosis of ventilator-associated pneumonia
por: Lorente, L, et al.
Publicado: (2004)

Ceftazidime reduces pulmonary hypertension in an ovine model of sepsis following smoke inhalation injury
por: Maybauer, DM, et al.
Publicado: (2005)

Continuous infusion versus intermittent infusion of ceftazidime for the treatment of pneumonia caused by Pseudomonas aeruginosa
por: Lorente, L, et al.
Publicado: (2005)

606. Efficacy and Safety of Ceftazidime-Avibactam Comparative Dosage Regimens in Patients with Kidney Injury: A Retrospective Cohort Study
por: Sait, Walaa Adel, et al.
Publicado: (2022)

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia
por: Nassar, YS, et al.
Publicado: (2015)

Optimizing the dosing regimen of linezolid in critically ill septic patients undergoing continuous hemodiafiltration using a pharmacokinetic/pharmacodynamic analysis and monte carlo simulation
por: Barrasa González, H, et al.
Publicado: (2015)

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
por: Das, Shampa, et al.
Publicado: (2019)

Subcutaneous pharmacokinetics and dosage regimen of cefotaxime in buffalo calves (Bubalus bubalis)
por: Sharma, Suresh Kumar, et al.
Publicado: (2006)

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen
por: Jang, Ji-Hun, et al.
Publicado: (2023)

Effective dosage of enoxaparin for intensive care patients
por: Robinson, S, et al.
Publicado: (2013)

Impact of myeloperoxidase dosage in acute coronary syndrome
por: Esporcatte, R, et al.
Publicado: (2005)

Burn variables and intensive care mortality in severe burn patients
por: Gianesello, L, et al.
Publicado: (2004)

Lactate in the burn patient
por: Herrero, EH, et al.
Publicado: (2015)

Comparison of bacterial isolated from burn wounds in ICU and burn ward patients
por: Mano, V, et al.
Publicado: (2011)

Remifentanil dosage in critically ill patients is independent of organ dysfunction
por: Kulier, A, et al.
Publicado: (2006)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Biomarkers of sepsis in burn patients
por: Oueslati, H, et al.
Publicado: (2010)

Relative adrenal insufficiency in burns
por: Mokline, A, et al.
Publicado: (2013)

Intraabdominal hypertension in burn patients
por: Mokline, A, et al.
Publicado: (2015)

0329. Beneficial effects of azithromycin combined with ceftazidime without activity against P. aeruginosa in a murine sepsis model of peritonitis by Pseudomonas aeruginosa
por: Pachón-Ibañez, ME, et al.
Publicado: (2014)

Micafungin concentrations 100 mg daily in plasma and burn eschars in patients with severe burn injuries
por: Agrifoglio, A, et al.
Publicado: (2015)

Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations
por: Li, Zhi-ling, et al.
Publicado: (2018)

Measurement of indocyanine green plasma disappearance rate by two different dosages
por: Sakka, S, et al.
Publicado: (2004)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy
por: Kline, Ellen G, et al.
Publicado: (2020)

P361: Biomedical waste management in hospitals: the case of large burned: the burn centre center of Abidjan
por: Oyourou, R, et al.
Publicado: (2013)

TI nulling and contrast conditions with a 0.15 mmol/kg dosage of MultiHance as compared to the standard 0.2 mmol/kg gadolinium dosage in patients with myocardial infarcts
por: Yamrozik, June A, et al.
Publicado: (2009)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Sepsis and multiple organ dysfunction in burn
por: Henrich, Sabrina F, et al.
Publicado: (2013)

Admission hyperglycemia increases mortality in burns
por: Messaadi, A, et al.
Publicado: (2005)

Inhalation injury in critical burn patients
por: Cachafeiro, L, et al.
Publicado: (2013)

Intraabdominal pressure in critical burn patients
por: Millan, PM
Publicado: (2015)

Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients
por: Druge, Stéphanie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mr5k3cph01eqlrgmo3rd1654ge